Cardio Diagnostics Holdings Inc. Common stock (CDIO) — 分析摘要
Cardio Diagnostics Holdings Inc. Common stock（CDIO）的市值为5.27百万美元，最近一年的营收同比增长了-57.5%。净利润率为-43832.5%。当前市盈率为-0.8倍。
核心要点
- 营收同比变化-57.5%
- 净利润率-43832.5%
- 市盈率-0.8倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比，CDIO的营收增长为-57.5%，市盈率为-0.8倍。
Cardio Diagnostics Holdings Inc. Common stock (CDIO)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -525.1x — 盈利不足以覆盖利息支出
营业利润率为 -44690.7% — 严重经营亏损
净利率为 -44771.8% — 亏损超过收入（可能含一次性费用）
最新报表显示自由现金流为负。
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
17
总部
CHICAGO, IL
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。